

## Rizatriptan Orally Disintegrating Formulation

Version 1.9      Revision Date: 10.10.2020      SDS Number: 809057-00010      Date of last issue: 23.03.2020  
Date of first issue: 22.07.2016

---

**SECTION 1. PRODUCT AND COMPANY IDENTIFICATION**

Product name : Rizatriptan Orally Disintegrating Formulation

**Manufacturer or supplier's details**

Company : Organon & Co.

Address : 30 Hudson Street, 33rd floor  
Jersey City, New Jersey, U.S.A 07302

Telephone : 551-430-6000

Emergency telephone number : 215-631-6999

E-mail address : EHSSTEWARD@organon.com

**Recommended use of the chemical and restrictions on use**

Recommended use : Pharmaceutical

---

**SECTION 2. HAZARDS IDENTIFICATION****GHS Classification**

Skin sensitisation : Category 1

Specific target organ toxicity - repeated exposure (Oral) : Category 2 (Cardio-vascular system)

**GHS label elements**

Hazard pictograms :



Signal word : Warning

Hazard statements : H317 May cause an allergic skin reaction.  
H373 May cause damage to organs (Cardio-vascular system) through prolonged or repeated exposure if swallowed.

Precautionary statements : **Prevention:**  
P260 Do not breathe dust.  
P272 Contaminated work clothing should not be allowed out of the workplace.  
P280 Wear protective gloves.  
**Response:**  
P302 + P352 IF ON SKIN: Wash with plenty of soap and water.  
P314 Get medical advice/ attention if you feel unwell.  
P333 + P313 If skin irritation or rash occurs: Get medical advice/ attention.  
P363 Wash contaminated clothing before reuse.

---

## Rizatriptan Orally Disintegrating Formulation

Version 1.9      Revision Date: 10.10.2020      SDS Number: 809057-00010      Date of last issue: 23.03.2020  
Date of first issue: 22.07.2016

**Disposal:**

P501 Dispose of contents/ container to an approved waste disposal plant.

**Other hazards which do not result in classification**

Dust contact with the eyes can lead to mechanical irritation.  
May form explosive dust-air mixture during processing, handling or other means.

**SECTION 3. COMPOSITION/INFORMATION ON INGREDIENTS**

Substance / Mixture : Mixture

**Components**

Chemical name	CAS-No.	Concentration (% w/w)
Cellulose	9004-34-6	>= 10 -< 30
Peppermint oil	8006-90-4	>= 1 -< 10
Starch	9005-25-8	< 10
Rizatriptan	145202-66-0	>= 1 -< 3

**SECTION 4. FIRST AID MEASURES**

General advice : In the case of accident or if you feel unwell, seek medical advice immediately.  
When symptoms persist or in all cases of doubt seek medical advice.

If inhaled : If inhaled, remove to fresh air.  
Get medical attention.

In case of skin contact : In case of contact, immediately flush skin with plenty of water.  
Remove contaminated clothing and shoes.  
Get medical attention.  
Wash clothing before reuse.  
Thoroughly clean shoes before reuse.

In case of eye contact : If in eyes, rinse well with water.  
Get medical attention if irritation develops and persists.

If swallowed : If swallowed, DO NOT induce vomiting.  
Get medical attention.  
Rinse mouth thoroughly with water.

Most important symptoms and effects, both acute and delayed : May cause an allergic skin reaction.  
May cause damage to organs through prolonged or repeated exposure if swallowed.  
Dust contact with the eyes can lead to mechanical irritation.

Protection of first-aiders : First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8).

Notes to physician : Treat symptomatically and supportively.

**SECTION 5. FIREFIGHTING MEASURES**

Suitable extinguishing media : Water spray  
Alcohol-resistant foam  
Carbon dioxide (CO<sub>2</sub>)  
Dry chemical

## Rizatriptan Orally Disintegrating Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 23.03.2020
1.9	10.10.2020	809057-00010	Date of first issue: 22.07.2016

---

- Unsuitable extinguishing media : None known.
- Specific hazards during fire-fighting : Avoid generating dust; fine dust dispersed in air in sufficient concentrations, and in the presence of an ignition source is a potential dust explosion hazard. Exposure to combustion products may be a hazard to health.
- Hazardous combustion products : Carbon oxides  
Nitrogen oxides (NO<sub>x</sub>)
- Specific extinguishing methods : Use extinguishing measures that are appropriate to local circumstances and the surrounding environment. Use water spray to cool unopened containers. Remove undamaged containers from fire area if it is safe to do so. Evacuate area.
- Special protective equipment for firefighters : In the event of fire, wear self-contained breathing apparatus. Use personal protective equipment.
- 

**SECTION 6. ACCIDENTAL RELEASE MEASURES**

- Personal precautions, protective equipment and emergency procedures : Use personal protective equipment. Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).
- Environmental precautions : Avoid release to the environment. Prevent further leakage or spillage if safe to do so. Retain and dispose of contaminated wash water. Local authorities should be advised if significant spillages cannot be contained.
- Methods and materials for containment and cleaning up : Sweep up or vacuum up spillage and collect in suitable container for disposal. Avoid dispersal of dust in the air (i.e., clearing dust surfaces with compressed air). Dust deposits should not be allowed to accumulate on surfaces, as these may form an explosive mixture if they are released into the atmosphere in sufficient concentration. Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable. Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.
- 

**SECTION 7. HANDLING AND STORAGE**

- Technical measures : Static electricity may accumulate and ignite suspended dust causing an explosion. Provide adequate precautions, such as electrical grounding and bonding, or inert atmospheres.
- Local/Total ventilation : Use only with adequate ventilation.
- Advice on safe handling : Do not get on skin or clothing. Do not breathe dust.
-

## Rizatriptan Orally Disintegrating Formulation

Version 1.9      Revision Date: 10.10.2020      SDS Number: 809057-00010      Date of last issue: 23.03.2020  
Date of first issue: 22.07.2016

- Do not swallow.  
Avoid contact with eyes.  
Wash skin thoroughly after handling.  
Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment  
Minimize dust generation and accumulation.  
Keep container closed when not in use.  
Keep away from heat and sources of ignition.  
Take precautionary measures against static discharges.  
Do not eat, drink or smoke when using this product.  
Take care to prevent spills, waste and minimize release to the environment.
- Hygiene measures : If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place.  
When using do not eat, drink or smoke.  
Contaminated work clothing should not be allowed out of the workplace.  
Wash contaminated clothing before re-use.  
The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls.
- Conditions for safe storage : Keep in properly labelled containers.  
Store in accordance with the particular national regulations.
- Materials to avoid : Do not store with the following product types:  
Strong oxidizing agents

## SECTION 8. EXPOSURE CONTROLS/PERSONAL PROTECTION

## Components with workplace control parameters

Components	CAS-No.	Value type (Form of exposure)	Control parameters / Permissible concentration	Basis
Cellulose	9004-34-6	TWA	10 mg/m <sup>3</sup>	AU OEL
	Further information: This value is for inhalable dust containing no asbestos and < 1% crystalline silica			
		TWA	10 mg/m <sup>3</sup>	ACGIH
Peppermint oil	8006-90-4	TWA (Mist)	10 mg/m <sup>3</sup>	AU OEL
Starch	9005-25-8	TWA	10 mg/m <sup>3</sup>	AU OEL
	Further information: This value is for inhalable dust containing no asbestos and < 1% crystalline silica			
		TWA	10 mg/m <sup>3</sup>	ACGIH
Rizatriptan	145202-66-0	TWA	10 µg/m <sup>3</sup> (OEB 3)	Internal
		Wipe limit	100 µg/100 cm <sup>2</sup>	Internal

- Engineering measures : All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment.  
Containment technologies suitable for controlling compounds

## Rizatriptan Orally Disintegrating Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 23.03.2020
1.9	10.10.2020	809057-00010	Date of first issue: 22.07.2016

---

are required to control at source and to prevent migration of the compound to uncontrolled areas (e.g., open-face containment devices).  
Minimize open handling.

**Personal protective equipment**

Respiratory protection	:	If adequate local exhaust ventilation is not available or exposure assessment demonstrates exposures outside the recommended guidelines, use respiratory protection.
Filter type	:	Particulates type
Hand protection	:	
Material	:	Chemical-resistant gloves
Remarks	:	Consider double gloving.
Eye protection	:	Wear safety glasses with side shields or goggles. If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles. Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols.
Skin and body protection	:	Work uniform or laboratory coat. Additional body garments should be used based upon the task being performed (e.g., sleevelets, apron, gauntlets, disposable suits) to avoid exposed skin surfaces. Use appropriate degowning techniques to remove potentially contaminated clothing.

**SECTION 9. PHYSICAL AND CHEMICAL PROPERTIES**

Appearance	:	powder
Colour	:	No data available
Odour	:	No data available
Odour Threshold	:	No data available
pH	:	No data available
Melting point/freezing point	:	No data available
Initial boiling point and boiling range	:	No data available
Flash point	:	Not applicable
Evaporation rate	:	No data available
Flammability (solid, gas)	:	May form explosive dust-air mixture during processing, handling or other means.
Flammability (liquids)	:	No data available
Upper explosion limit / Upper	:	No data available

# SAFETY DATA SHEET



## Rizatriptan Orally Disintegrating Formulation



Version 1.9      Revision Date: 10.10.2020      SDS Number: 809057-00010      Date of last issue: 23.03.2020  
Date of first issue: 22.07.2016

---

flammability limit

Lower explosion limit / Lower flammability limit : No data available

Vapour pressure : No data available

Relative vapour density : No data available

Relative density : No data available

Density : No data available

Solubility(ies)  
Water solubility : No data available

Partition coefficient: n-octanol/water : No data available

Auto-ignition temperature : No data available

Decomposition temperature : No data available

Viscosity  
Viscosity, kinematic : No data available

Explosive properties : Not explosive

Oxidizing properties : The substance or mixture is not classified as oxidizing.

Molecular weight : No data available

Particle size : No data available

---

### SECTION 10. STABILITY AND REACTIVITY

Reactivity : Not classified as a reactivity hazard.

Chemical stability : Stable under normal conditions.

Possibility of hazardous reactions : May form explosive dust-air mixture during processing, handling or other means.  
Can react with strong oxidizing agents.

Conditions to avoid : Heat, flames and sparks.  
Avoid dust formation.

Incompatible materials : Oxidizing agents

Hazardous decomposition products : No hazardous decomposition products are known.

---

### SECTION 11. TOXICOLOGICAL INFORMATION

Exposure routes : Inhalation  
Skin contact  
Ingestion  
Eye contact

## Rizatriptan Orally Disintegrating Formulation

Version 1.9      Revision Date: 10.10.2020      SDS Number: 809057-00010      Date of last issue: 23.03.2020  
Date of first issue: 22.07.2016

---

**Acute toxicity**

Not classified based on available information.

**Product:**

Acute oral toxicity : Acute toxicity estimate: > 2,000 mg/kg  
Method: Calculation method

**Components:****Cellulose:**

Acute oral toxicity : LD50 (Rat): > 5,000 mg/kg

Acute inhalation toxicity : LC50 (Rat): > 5.8 mg/l  
Exposure time: 4 h  
Test atmosphere: dust/mist

Acute dermal toxicity : LD50 (Rabbit): > 2,000 mg/kg

**Peppermint oil:**

Acute oral toxicity : LD50 (Rat): > 2,000 mg/kg

Acute dermal toxicity : LD50 (Rabbit): > 5,000 mg/kg

**Starch:**

Acute oral toxicity : LD50 (Rat): > 5,000 mg/kg

Acute dermal toxicity : LD50 (Rabbit): > 2,000 mg/kg

**Rizatriptan:**

Acute oral toxicity : LD50 (Rat): 2,227 mg/kg

LD50 (Mouse): 700 - 1,631 mg/kg

**Skin corrosion/irritation**

Not classified based on available information.

**Components:****Peppermint oil:**

Species : Rabbit  
Result : Skin irritation  
Remarks : Based on data from similar materials

**Rizatriptan:**

Species : Rabbit  
Result : No skin irritation

**Serious eye damage/eye irritation**

Not classified based on available information.

## Rizatriptan Orally Disintegrating Formulation

Version 1.9      Revision Date: 10.10.2020      SDS Number: 809057-00010      Date of last issue: 23.03.2020  
Date of first issue: 22.07.2016

---

**Components:****Peppermint oil:**

Species : Rabbit  
Result : Irritation to eyes, reversing within 21 days  
Remarks : Based on data from similar materials

**Starch:**

Species : Rabbit  
Result : No eye irritation

**Rizatriptan:**

Species : Bovine cornea  
Remarks : Moderate eye irritation

**Respiratory or skin sensitisation****Skin sensitisation**

May cause an allergic skin reaction.

**Respiratory sensitisation**

Not classified based on available information.

**Components:****Peppermint oil:**

Test Type : Local lymph node assay (LLNA)  
Exposure routes : Skin contact  
Species : Mouse  
Method : OECD Test Guideline 429  
Result : positive  
Remarks : Based on data from similar materials

Assessment : Probability or evidence of skin sensitisation in humans

**Starch:**

Test Type : Maximisation Test  
Exposure routes : Skin contact  
Species : Guinea pig  
Result : negative

**Rizatriptan:**

Test Type : Maximisation Test  
Exposure routes : Dermal  
Species : Guinea pig  
Assessment : Does not cause skin sensitisation.  
Result : negative

**Chronic toxicity****Germ cell mutagenicity**

Not classified based on available information.



## Rizatriptan Orally Disintegrating Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 23.03.2020
1.9	10.10.2020	809057-00010	Date of first issue: 22.07.2016

---

**Components:****Cellulose:**

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)  
Result: negative

Test Type: In vitro mammalian cell gene mutation test  
Result: negative

Genotoxicity in vivo : Test Type: Mammalian erythrocyte micronucleus test (in vivo cytogenetic assay)  
Species: Mouse  
Application Route: Ingestion  
Result: negative

**Starch:**

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)  
Result: negative

**Rizatriptan:**

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)  
Result: negative

Test Type: Alkaline elution assay  
Result: negative

Test Type: In vitro mammalian cell gene mutation test  
Result: negative

Test Type: Chromosome aberration test in vitro  
Result: negative

Genotoxicity in vivo : Test Type: Mammalian erythrocyte micronucleus test (in vivo cytogenetic assay)  
Species: Mouse  
Application Route: Oral  
Result: negative

**Carcinogenicity**

Not classified based on available information.

**Components:****Cellulose:**

Species : Rat  
Application Route : Ingestion  
Exposure time : 72 weeks  
Result : negative

**Rizatriptan:**

Species : Mouse  
Application Route : Oral

## Rizatriptan Orally Disintegrating Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 23.03.2020
1.9	10.10.2020	809057-00010	Date of first issue: 22.07.2016

---

Exposure time : 100 weeks  
 NOAEL : 125 mg/kg body weight  
 Result : negative

Species : Rat  
 Application Route : Oral  
 Exposure time : 106 weeks  
 NOAEL : 106 mg/kg body weight  
 Result : negative

**Reproductive toxicity**

Not classified based on available information.

**Components:****Cellulose:**

Effects on fertility : Test Type: One-generation reproduction toxicity study  
 Species: Rat  
 Application Route: Ingestion  
 Result: negative

Effects on foetal development : Test Type: Fertility/early embryonic development  
 Species: Rat  
 Application Route: Ingestion  
 Result: negative

**Rizatriptan:**

Effects on fertility : Test Type: Fertility/early embryonic development  
 Species: Rat, female  
 Application Route: Oral  
 Fertility: LOAEL: 100 mg/kg body weight  
 Symptoms: altered estrus cycles  
 Result: No effects on fertility and early embryonic development were detected.

Test Type: Fertility/early embryonic development  
 Species: Rat, male  
 Application Route: Oral  
 Fertility: NOAEL: 250 mg/kg body weight  
 Result: No effects on fertility and early embryonic development were detected.

Effects on foetal development : Test Type: Embryo-foetal development  
 Species: Rat  
 Application Route: Oral  
 Developmental Toxicity: LOAEL: 10 mg/kg body weight  
 Result: No teratogenic effects, Embryo-foetal toxicity

Test Type: Embryo-foetal development  
 Species: Rabbit  
 Application Route: Oral  
 Developmental Toxicity: LOAEL: 100 mg/kg body weight  
 Result: No teratogenic effects, Embryo-foetal toxicity  
 Remarks: The effects were seen only at maternally toxic dos-

## Rizatriptan Orally Disintegrating Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 23.03.2020
1.9	10.10.2020	809057-00010	Date of first issue: 22.07.2016

---

es.

Reproductive toxicity - Assessment : Some evidence of adverse effects on development, based on animal experiments.

**STOT - single exposure**

Not classified based on available information.

**Components:****Rizatriptan:**

Assessment : May cause drowsiness or dizziness.

**STOT - repeated exposure**

May cause damage to organs (Cardio-vascular system) through prolonged or repeated exposure if swallowed.

**Components:****Rizatriptan:**

Target Organs : Cardio-vascular system  
Assessment : Causes damage to organs through prolonged or repeated exposure.

**Repeated dose toxicity****Components:****Cellulose:**

Species : Rat  
NOAEL :  $\geq 9,000$  mg/kg  
Application Route : Ingestion  
Exposure time : 90 Days

**Starch:**

Species : Rat  
NOAEL :  $\geq 2,000$  mg/kg  
Application Route : Skin contact  
Exposure time : 28 Days  
Method : OECD Test Guideline 410

**Rizatriptan:**

Species : Rat  
LOAEL : 1 mg/kg  
Application Route : Oral  
Exposure time : 14 Weeks  
Symptoms : Dilatation of the pupil, Increased pulse rate, Redness

Species : Dog  
LOAEL : 0.05 mg/kg  
Application Route : Intravenous  
Exposure time : 2 Weeks  
Symptoms : Dilatation of the pupil, Increased pulse rate, Redness

## Rizatriptan Orally Disintegrating Formulation

Version 1.9      Revision Date: 10.10.2020      SDS Number: 809057-00010      Date of last issue: 23.03.2020  
Date of first issue: 22.07.2016

---

Species : Dog  
LOAEL : 0.2 mg/kg  
Application Route : Oral  
Exposure time : 1 yr  
Symptoms : Dilatation of the pupil

**Aspiration toxicity**

Not classified based on available information.

**Experience with human exposure****Components:****Rizatriptan:**

Ingestion : Target Organs: Cardio-vascular system  
Symptoms: asthenia, Fatigue, Pain, Dizziness, Weakness, Drowsiness

---

**SECTION 12. ECOLOGICAL INFORMATION****Ecotoxicity****Components:****Cellulose:**

Toxicity to fish : LC50 (Oryzias latipes (Japanese medaka)): > 100 mg/l  
Exposure time: 48 h  
Remarks: Based on data from similar materials

**Peppermint oil:**

Toxicity to fish : LL50 (Danio rerio (zebra fish)): > 10 - 100 mg/l  
Exposure time: 96 h  
Remarks: Based on data from similar materials

Toxicity to daphnia and other aquatic invertebrates : EL50 (Daphnia magna (Water flea)): > 10 - 100 mg/l  
Exposure time: 48 h  
Remarks: Based on data from similar materials

Toxicity to algae/aquatic plants : EL50 (Desmodesmus subspicatus (green algae)): > 10 - 100 mg/l  
Exposure time: 72 h  
Remarks: Based on data from similar materials

Toxicity to microorganisms : EC10: 51 mg/l  
Exposure time: 3 h  
Remarks: Based on data from similar materials

**Rizatriptan:**

Toxicity to fish : LC50 (Pimephales promelas (fathead minnow)): > 1,000 mg/l  
Exposure time: 96 h

Toxicity to daphnia and other : EC50 (Daphnia magna (Water flea)): 1,000 mg/l

## Rizatriptan Orally Disintegrating Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 23.03.2020
1.9	10.10.2020	809057-00010	Date of first issue: 22.07.2016

---

aquatic invertebrates	Exposure time: 48 h
Toxicity to algae/aquatic plants	: EC50 (Pseudokirchneriella subcapitata (green algae)): > 100 mg/l Exposure time: 72 h Method: OECD Test Guideline 201
	NOEC (Pseudokirchneriella subcapitata (green algae)): 48 mg/l Exposure time: 72 h Method: OECD Test Guideline 201
Toxicity to fish (Chronic toxicity)	: NOEC (Pimephales promelas (fathead minnow)): 9.6 mg/l Exposure time: 32 d Method: OECD Test Guideline 210
Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity)	: NOEC (Daphnia magna (Water flea)): 110 mg/l Exposure time: 21 d Method: OECD Test Guideline 211
Toxicity to microorganisms	: EC50: > 1,000 mg/l Exposure time: 3 h Test Type: Respiration inhibition Method: OECD Test Guideline 209
	NOEC: 1,000 mg/l Exposure time: 3 h Test Type: Respiration inhibition Method: OECD Test Guideline 209

**Persistence and degradability****Components:****Cellulose:**

Biodegradability : Result: Readily biodegradable.

**Peppermint oil:**

Biodegradability : Result: Readily biodegradable.  
Remarks: Based on data from similar materials

**Rizatriptan:**

Biodegradability : Result: Not readily biodegradable.  
Biodegradation: 50 %  
Exposure time: 13 d  
Method: OECD Test Guideline 314

**Bioaccumulative potential****Components:****Peppermint oil:**

Partition coefficient: n- : log Pow: > 4

# SAFETY DATA SHEET



## Rizatriptan Orally Disintegrating Formulation



Version 1.9      Revision Date: 10.10.2020      SDS Number: 809057-00010      Date of last issue: 23.03.2020  
Date of first issue: 22.07.2016

---

octanol/water      Remarks: Based on data from similar materials

### Rizatriptan:

Partition coefficient: n-octanol/water      :    log Pow: -0.649

### Mobility in soil

### Components:

### Rizatriptan:

Distribution among environmental compartments      :    log Koc: 3.83  
Method: OECD Test Guideline 106

### Other adverse effects

No data available

---

## SECTION 13. DISPOSAL CONSIDERATIONS

### Disposal methods

Waste from residues      :    Dispose of in accordance with local regulations.  
Contaminated packaging      :    Empty containers should be taken to an approved waste handling site for recycling or disposal.  
If not otherwise specified: Dispose of as unused product.

---

## SECTION 14. TRANSPORT INFORMATION

### International Regulations

#### UNRTDG

Not regulated as a dangerous good

#### IATA-DGR

Not regulated as a dangerous good

#### IMDG-Code

Not regulated as a dangerous good

### Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code

Not applicable for product as supplied.

### National Regulations

#### ADG

Not regulated as a dangerous good

---

## SECTION 15. REGULATORY INFORMATION

### Safety, health and environmental regulations/legislation specific for the substance or mixture

Prohibition/Licensing Requirements      :    There is no applicable prohibition, authorisation and restricted use requirements, including for carcino-

---

# SAFETY DATA SHEET



## Rizatriptan Orally Disintegrating Formulation



Version 1.9      Revision Date: 10.10.2020      SDS Number: 809057-00010      Date of last issue: 23.03.2020  
Date of first issue: 22.07.2016

---

gens referred to in Schedule 10 of the model WHS Act and Regulations.

**The components of this product are reported in the following inventories:**

AICS : not determined  
DSL : not determined  
IECSC : not determined

---

### SECTION 16. OTHER INFORMATION

**Further information**

Revision Date : 10.10.2020  
Sources of key data used to compile the Safety Data Sheet : Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agency, <http://echa.europa.eu/>  
Date format : dd.mm.yyyy

**Full text of other abbreviations**

ACGIH : USA. ACGIH Threshold Limit Values (TLV)  
AU OEL : Australia. Workplace Exposure Standards for Airborne Contaminants.  
ACGIH / TWA : 8-hour, time-weighted average  
AU OEL / TWA : Exposure standard - time weighted average

AIIC - Australian Inventory of Industrial Chemicals; ANTT - National Agency for Transport by Land of Brazil; ASTM - American Society for the Testing of Materials; bw - Body weight; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; Nch - Chilean Norm; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NOM - Official Mexican Norm; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation,

# SAFETY DATA SHEET



## Rizatriptan Orally Disintegrating Formulation



Version	Revision Date:	SDS Number:	Date of last issue: 23.03.2020
1.9	10.10.2020	809057-00010	Date of first issue: 22.07.2016

---

tion, Authorisation and Restriction of Chemicals; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TDG - Transportation of Dangerous Goods; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative; WHMIS - Workplace Hazardous Materials Information System

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

AU / EN